SEC Form 4 · accession 0001019056-17-000288

Aptevo Therapeutics Inc. · APVO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — SVP, CFO and Treasurer

Period of report

Mar 1, 2017

Accepted (ET)

Mar 13, 2017 · 9:05 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001671584

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Mar 1, 2017	M	7,320	—	A	24,386	D
Common Stock	Mar 1, 2017	F	1,936	$2.02	D	22,450	D
Common Stock^F1	Mar 1, 2017	M	6,746	—	A	29,196	D
Common Stock	Mar 10, 2017	F	1,785	$1.78	D	27,411	D
Common Stock^F1	Mar 10, 2017	M	18,863	—	A	46,274	D
Common Stock	Mar 10, 2017	F	4,990	$1.78	D	41,284	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restricted Stock Unit^F1,F2	—	Mar 1, 2017	M	7,320	D	—	—	Common Stock	7,320	72,334	D
Restricted Stock Unit^F1,F3	—	Mar 10, 2017	M	6,746	D	—	—	Common Stock	6,746	65,588	D
Restricted Stock Unit^F1,F4	—	Mar 10, 2017	M	18,863	D	—	—	Common Stock	18,863	46,725	D

F1Each RSU converts into the Issuer's common stock on a one-for-one basis.
F2The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs vest as follows: 7,320 on March 1, 2017, 7,320 on March 1, 2018 and 7,318 on March 1, 2019.
F3The RSUs were originally issued by Emergent on March 10, 2015 and, as a result of the Spin-off, were adjusted and assumed by the Issuer. The RSUs vest as follows: 6,746 on March 10, 2017 and 6,747 on March 10, 2018.
F4The RSUs were originally issued by Emergent on March 11, 2014 and, as a result of the Spin-off, were adjusted and assumed by the Issuer. The RSUs fully vested on March 10, 2017.